Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.8
2.7
Journals
Brain Sciences
Special Issues
New Advances in the Development of New Drugs and Treatment...
share announcement

New Advances in the Development of New Drugs and Treatment Targets for Brain Cancers (2nd Edition)

A special issue of Brain Sciences (ISSN 2076-3425). This special issue belongs to the section "Neuro-oncology".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 2353

Special Issue Editors

Dr. Luis Ibarra

E-Mail Website1 Website2
Guest Editor
Institute of Environmental Biotechnology and Health (INBIAS), National Council for Scientific and Technical Research (CONICET) and National University of Río Cuarto (UNRC), Rio Cuarto, Argentina
Interests: nanomedicine; cell therapy; tumor microenvironment; photodynamic therapy; cell targeting
Special Issues, Collections and Topics in MDPI journals
Dr. Laura Natalia Milla Sanabria

E-Mail Website
Guest Editor
Institute of Environmental Biotechnology and Health (INBIAS), National Council for Scientific and Technical Research (CONICET) and National University of Río Cuarto (UNRC), Rio Cuarto, Argentina
Interests: glioblastoma; photodynamic therapy; cancer stem cells; resistance
Special Issues, Collections and Topics in MDPI journals
Dr. Nuria Arias-Ramos

E-Mail Website
Guest Editor
Biomedical Magnetic Resonance Lab, Department of Endocrine and Nervous System Pathophysiology, Instituto de Investigaciones Biomedicas Alberto Sols (IIBM), CSIC-UAM, 28029-Madrid, Spain
Interests: magnetic resonance imaging (MRI); magnetic resonance spectroscopy (MRS); positron emission tomography (PET); brain tumors; nanoparticles; contrast agents
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Brain malignancies pose a substantial obstacle for the field of oncology and the advancement of pharmaceuticals. Historically, the treatment of brain tumors has been challenging due to their physical and molecular characteristics. The tumor's exposure to systemic therapy may be diminished by the blood–tumor barrier (BTB), which may differ from the normal blood–brain barrier (BBB) and frequently complicate complete surgery. Moreover, brain tumors possess microenvironmental characteristics that are remarkably distinct and intricately associated with developmental factors. The tumor microenvironment (TME) is composed primarily of specialized cells such as brain endothelial cells, astrocytes, neurons and microglia, which are concentrated in the brain. In addition, it has been shown that unique subpopulations of cells derived from the bone marrow infiltrate both primary and metastatic brain malignancies. The potential of the TME as both a diagnostic marker and a therapeutic target for brain malignancies has been established.

We declare a call for papers for the second series of our Special Issue "New Advances in the Development of New Drugs and Treatment Targets for Brain Cancers (2nd Edition)" with great enthusiasm. This series demonstrates our dedication to collecting and presenting the most recent research, advancements and difficulties in the field of brain tumors. This resource enhances the comprehension of various primary brain cancers by examining novel therapy approaches and targeted medications, while delving into the significance of brain tumors at the cellular and molecular levels. For this second series, we are specifically seeking papers that expand upon the research offered in the first series. We are looking for fresh viewpoints, approaches to unresolved issues and creative solutions.

Dr. Luis Exequiel Ibarra
Dr. Laura Natalia Milla Sanabria
Dr. Nuria Arias-Ramos
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Brain Sciences is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gliomas
  • targeted therapy
  • blood–brain barrier
  • tumor microenvironment
  • molecular and cellular biology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 5489 KiB  
Article
Naringenin Exhibits Antiglioma Activity Related to Aryl Hydrocarbon Receptor Activity and IL-6, CCL2, and TNF-α Expression
by Monique Reis de Santana, Deivison Silva Argolo, Irlã Santos Lima, Cleonice Creusa dos Santos, Maurício Moraes Victor, Gabriel dos Santos Ramos, Ravena Pereira do Nascimento, Henning Ulrich and Silvia Lima Costa
Brain Sci. 2025, 15(3), 325; https://doi.org/10.3390/brainsci15030325 - 20 Mar 2025
Viewed by 397
Abstract
Background: Glioblastoma (GBM) is a highly aggressive brain tumor characterized by rapid cell proliferation, invasive behavior, and chemoresistance. The aryl hydrocarbon receptor (AhR) is implicated in chemoresistance and immune evasion, making it a promising therapeutic target. Natural compounds such as flavonoids have gained [...] Read more.
Background: Glioblastoma (GBM) is a highly aggressive brain tumor characterized by rapid cell proliferation, invasive behavior, and chemoresistance. The aryl hydrocarbon receptor (AhR) is implicated in chemoresistance and immune evasion, making it a promising therapeutic target. Natural compounds such as flavonoids have gained attention for their anti-inflammatory, antioxidant, and anticancer properties. Among them, naringenin, a citrus-derived flavonoid, exerts antiproliferative, pro-apoptotic, and immunomodulatory effects. Objectives: This study investigated the antiglioma effects of the flavonoid naringenin on the viability, growth, and migration of glioma cells and its potential role as an AhR modulator. Methods: Human (U87) and rat (C6) glioma cell lines were exposed to naringenin (10–300 µM) alone or in combination with the AhR agonist indole-3-carbinol (50 µM) for 24 to 48 h. Cell viability, scratch wound, and cell migration assays were performed. The expression of inflammatory markers was also analyzed by RT-qPCR. Results: Naringenin exerted dose- and time-dependent inhibition of cell viability and migration. The treatment decreased the gene expression of interleukin-6 (IL-6) and chemokine (CCL2), alongside increased tumor necrosis factor-alpha (TNF-α) expression, an effect reversed by the AhR agonist. Conclusions: These findings highlight naringenin’s potential as an antiglioma agent and its role in AhR signaling. Full article
(This article belongs to the Special Issue New Advances in the Development of New Drugs and Treatment Targets for Brain Cancers (2nd Edition))
►▼ Show Figures

Figure 1

16 pages, 3313 KiB  
Article
Erlotinib Improves the Response of Glioblastoma Cells Resistant to Photodynamic Therapy
by Karen Olthoff, Ayelén D. Nigra and Laura N. Milla Sanabria
Brain Sci. 2024, 14(12), 1192; https://doi.org/10.3390/brainsci14121192 - 26 Nov 2024
Viewed by 1103
Abstract
Background: Glioblastoma (GBM) is the most common and deadly type of brain cancer in adults. Dysregulation of receptor tyrosine kinase pathways, such as the epidermal growth factor receptor (EGFR), contributes to therapeutic resistance. Drugs that inhibit tyrosine kinase activity and monoclonal antibodies against [...] Read more.
Background: Glioblastoma (GBM) is the most common and deadly type of brain cancer in adults. Dysregulation of receptor tyrosine kinase pathways, such as the epidermal growth factor receptor (EGFR), contributes to therapeutic resistance. Drugs that inhibit tyrosine kinase activity and monoclonal antibodies against EGFR are strategies used in clinical trials. Photodynamic therapy (PDT) is a tumor treatment that involves the administration of a photosensitizing drug, followed by its activation with visible light, which causes cell death due to oxidative stress. Although PDT helps prolong median survival in patients with GBM, complete remission has not been achieved. Populations of GBM cells have been obtained from the T98G line resistant to PDT with methyl-5-aminolevulinic acid (Me-ALA) for characterization, comparing them with the original parental population. Objective: The objective of this work was to evaluate the general response of T98G GBM cells resistant to PDT when EGFR activity is inhibited with the drug erlotinib. Methods and Results: It has been observed that the administration of the EGFR inhibitor drug in combination with PDT reduced viability (MTT) in resistant populations compared to PDT alone. Furthermore, the PpIX content (flow cytometry) was increased in the resistant population when cells were incubated with Me-ALA and erlotinib. Erlotinib prevented cell proliferation of parental and resistant spheroids. Wound closure was reduced in both parental and PDT-resistant populations. Conclusions: Our results indicate that EGFR activation would be relevant in the resistance of GBM cells to PDT. Full article
(This article belongs to the Special Issue New Advances in the Development of New Drugs and Treatment Targets for Brain Cancers (2nd Edition))
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop